0746 GMT - Novartis's significant profit and sales beat could close the gap between its mid-term growth guidance that is clearly above market's expectations, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's key drugs overall exceeded consensus with heart drug Entresto its best-selling medicine, despite prostate-cancer drug Pluvicto being shy of consensus, the analyst says. "This quarterly (and annual) results add on to a continuous streak of results where Novartis beats their own and the market's expectations," he said. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 31, 2025 02:46 ET (07:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.